Documents

Record growth, new product launch, and capital raise drive path to breakeven and value creation.

Margin expansion and growth momentum set the stage for cash flow breakeven by 2027.

Core testing revenue up 99% year-on-year, with strong growth and new product launches ahead.

Core test sales surged 113% year-over-year, driving growth amid legacy product exit and cost reductions.

Core test volumes up 90% year-on-year, driving growth and nearing regional break-even.

Core test volumes surged, costs fell, and clean revenue growth is set to accelerate from Q3.

30% revenue growth and improved loss, with strong cash and focus on diagnostics and UK expansion.

Record core test growth and 30% revenue increase set up for breakeven and deal catalysts in FY2026.

FY revenue guidance raised, break-even targeted, and AUD 14.5M secured for expansion.

Diagnostic test growth, clinical breakthroughs, and global expansion drive strong outlook.

Microba leverages microbiome science to disrupt chronic disease care and drive global growth.

Revenue up 147% and net loss halved as testing sales accelerate and strategic growth initiatives advance.

Revenue up 102% YoY, MetaXplore sales up 195%, and strong growth outlook in diagnostics and therapeutics.